Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, van Beekhuizen S, Yuan Z, Mendes J, Lam A, He J, Ammann E, Kumar S. Facon T, et al. Among authors: van beekhuizen s. Adv Ther. 2022 May;39(5):1976-1992. doi: 10.1007/s12325-022-02083-8. Epub 2022 Mar 5. Adv Ther. 2022. PMID: 35246820 Free PMC article.
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
Dimopoulos MA, Cavo M, Mateos MV, Facon T, Heeg B, van Beekhuizen S, Gebregergish SB, Nair S, Pisini M, Lam A, Slavcev M. Dimopoulos MA, et al. Among authors: van beekhuizen s. Leuk Lymphoma. 2020 Mar;61(3):714-720. doi: 10.1080/10428194.2019.1682571. Epub 2019 Nov 5. Leuk Lymphoma. 2020. PMID: 31686559
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, van Beekhuizen S, Yuan Z, Mendes J, Lam A, He J, Ammann E, Kumar S. Facon T, et al. Among authors: van beekhuizen s. Adv Ther. 2022 Aug;39(8):3868-3869. doi: 10.1007/s12325-022-02211-4. Adv Ther. 2022. PMID: 35764866 Free PMC article. No abstract available.
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer.
De Santis M, Breijo SM, Robinson P, Capone C, Pascoe K, Van Sanden S, Hashim M, Trevisan M, Daly C, Reitsma F, van Beekhuizen S, Ruan H, Heeg B, Verzoni E. De Santis M, et al. Among authors: van beekhuizen s. Adv Ther. 2024 Aug;41(8):3039-3058. doi: 10.1007/s12325-024-02918-6. Epub 2024 Jul 3. Adv Ther. 2024. PMID: 38958846 Free PMC article. Review.
Preparation of antibodies against subclasses of human IgG.
Goosen PC, Van Beekhuizen S, Droogh C, De Lange G. Goosen PC, et al. Among authors: van beekhuizen s. J Immunol Methods. 1981;40(3):339-44. doi: 10.1016/0022-1759(81)90365-3. J Immunol Methods. 1981. PMID: 6788852 No abstract available.